Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Iako je re o sastojku to se uglavnom dobro podnosi, redovna i pravilna primena kljuna je za postizanje najboljih rezultata
Common side effects include nausea, vomiting, diarrhoea, and decreased appetite, similar to other GLP-1 medications, though women with PCOS may need additional monitoring for hormonal changes
Consider a Premier plan if you want more freedom when it comes to choosing your doctor
Clinical Trial Evidence The head-to-head comparison comes from the SURPASS clinical trial program for diabetes and SURMOUNT program for weight loss
:format(webp))
